Turning a blind eye to anti-VEGF toxicities

Journal of Clinical Investigation

Volumn 122, Issue 11, 2012, Pages 3849-3851

  Quaggin, Susan E ^a  

^a MOUNT SINAI HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CRE RECOMBINASE; VASCULOTROPIN A; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR;

BLINDNESS; BLOOD VESSEL PERMEABILITY; CELL DIFFERENTIATION; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; COLOR VISION; GENE DELETION; HUMAN; NEPHROTOXICITY; NONHUMAN; NOTE; PHOTORECEPTOR; PIGMENT EPITHELIUM; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETINA DISEASE; THROMBOTIC THROMBOCYTOPENIC PURPURA;

ANIMALS; BLINDNESS; EYE PROTEINS; RETINAL CONE PHOTORECEPTOR CELLS; RETINAL PIGMENT EPITHELIUM; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84868623614     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI65509     Document Type: Note

References (17)

1. Aiello LP, et al. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc Natl Acad Sci U S A. 1995;92(23):10457- 10461.
2. Campochiaro PA. Anti-vascular endothelial growth factor treatment for retinal vein occlusions. Ophthalmologica. 2012;227(suppl 1):30-35.
3. Ho AC, et al. Anti-vascular endothelial growth factor pharmacotherapy for diabetic macular edema: a report by the American Academy of Ophthalmology [published online ahead of print August 20, 2012]. Ophthalmology. doi:10.1016/j.ophtha.2012.07.058.
4. Ip MS, et al. Anti-vascular endothelial growth factor pharmacotherapy for age-related macular degeneration: a report by the American Academy of Ophthalmology. Ophthalmology. 2008;115(10):1837-1846.
5. Pece A, Isola V, Piermarocchi S, Calori G. Efficacy and safety of anti-vascular endothelial growth factor (VEGF) therapy with intravitreal ranibizumab (Lucentis) for naive retinal vein occlusion: 1-year follow-up. Br J Ophthalmol. 2011;95(1):56-68.
6. Rosenfeld PJ, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1419-1431. (Pubitemid 44511557)
7. Chun DW, Heier JS, Topping TM, Duker JS, Bankert JM. A pilot study of multiple intravitreal injections of ranibizumab in patients with center-involving clinically significant diabetic macular edema. Ophthalmology. 2006;113(10):1706-1712. (Pubitemid 44442451)
8. Kurihara T, Westenskow PD, Bravo S, Aguilar E, Friedlander M. Targeted deletion of Vegfa in adult mice induces vision loss. J Clin Invest. 2012;122(11):4213-4217.
9. Carmeliet P, et al. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature. 1996;380(6573):435-439. (Pubitemid 26102719)
10. Gerber HP, et al. VEGF is required for growth and survival in neonatal mice. Development. 1999;126(6):1149-1159.
11. Eremina V, et al. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med. 2008;358(11):1129-1136. (Pubitemid 351398487)
12. Frangie C, Lefaucheur C, Medioni J, Jacquot C, Hill GS, Nochy D. Renal thrombotic microangiopathy caused by anti-VEGF-antibody treatment for metastatic renal-cell carcinoma. Lancet Oncol. 2007;8(2):177-178. (Pubitemid 46158384)
13. Eremina V, et al. Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J Clin Invest. 2003;111(5):707-716. (Pubitemid 36278589)
14. Levine RJ, et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med. 2004;350(7):672-683. (Pubitemid 38364626)
15. Maynard SE, et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest. 2003;111(5):649-658.
16. Saint-Geniez M, et al. Endogenous VEGF is required for visual function: evidence for a survival role on muller cells and photoreceptors. PLoS One. 2008;3(11):e3554.
17. Dorrell MI, Aguilar E, Scheppke L, Barnett FH, Friedlander M. Combination angiostatic therapy completely inhibits ocular and tumor angiogenesis. Proc Natl Acad Sci U S A. 2007;104(3):967-972. (Pubitemid 46154720)